logo
Brad Arnold of 3 Doors Down reveals stage 4 kidney cancer diagnosis: 'I have no fear'

Brad Arnold of 3 Doors Down reveals stage 4 kidney cancer diagnosis: 'I have no fear'

USA Today07-05-2025

Brad Arnold of 3 Doors Down reveals stage 4 kidney cancer diagnosis: 'I have no fear'
It's not Brad Arnold's time to throw in the towel.
The rock musician and 3 Doors Down lead vocalist, 46, opened up about his health struggles in a May 7 video shared on the band's social media pages. Arnold revealed to fans he was diagnosed with advanced stage kidney cancer after a recent hospital visit.
"I've got some not-so-good news for you today," Arnold said. "So, I'd been sick a couple of weeks ago and then went to the hospital and got checked out and had actually got the diagnosis that I had clear cell renal carcinoma that had metastasized into my lung. And it's stage 4, and that's not real good."
According to the Cleveland Clinic, clear cell renal cell carcinoma is the most common form of kidney cancer. The disease occurs when the cells lining the small tubes that filter waste from the blood rapidly multiply, after which one or more tumors form. The cancer cells resemble clear bubbles when viewed through a microscope.
While there is no known cause for the cancer, per the Cleveland Clinic, factors such as tobacco use, obesity, high blood pressure and chronic kidney disease can increase a person's risk. Treatments include surgery, ablative (injection-based) therapies, immunotherapy and targeted therapy.
'I want to keep going': Michael Bolton speaks out on brain cancer diagnosis
Arnold also shared that his health ordeal has forced 3 Doors Down to cancel its upcoming Summer of '99 Tour. Despite the severe prognosis, the singer shared an optimistic outlook on his recovery, citing his religious faith.
"You know what? We serve a mighty God, and he can overcome anything. So, I have no fear. I really, sincerely am not scared of it at all," Arnold concluded.
"I'd love for you to lift me up in prayer every chance you get. And I think it's time for me to maybe go listen to 'It's Not My Time' a little bit. Thank you, guys so much. God loves you. We love you. See ya."
Teddi Mellencamp has stage 4 melanoma. What's next?
Arnold has served as frontman for 3 Doors Down since the rock band's 1996 formation. The group broke out in 2000 with the release of its debut album "The Better Life," which featured the No. 1 post-grunge banger "Kryptonite."
"It's Not My Time," taken from the band's 2008 self-titled album, offers a sentiment of resilience amid adversity with the song's emotional lyrics: "It's not my time, I'm not going / There's a fear in me, it's not showing / This could be the end of me and everything I know / But it's not my time."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought

Yahoo

time2 hours ago

  • Yahoo

Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought

Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. 'Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure,' a Novo Nordisk spokesperson told The Independent. 'Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in cardiovascular death, stroke, and myocardial infarction.' A request for comment from Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.

Trent Alexander-Arnold explains decision to change shirt name at Real Madrid
Trent Alexander-Arnold explains decision to change shirt name at Real Madrid

Yahoo

time2 hours ago

  • Yahoo

Trent Alexander-Arnold explains decision to change shirt name at Real Madrid

Trent Alexander-Arnold has explained why he has opted to change the name on the back of his shirt following his Real Madrid arrival. Alexander-Arnold, 26, was unveiled as a Galactico on Thursday afternoon, surprising fans as he gave his welcome speech in fluent Spanish. Advertisement Watch Trent Alexander-Arnold's Real Madrid debut at the Club World Cup free on DAZN. Sign up here now. It's not the only surprise the ex-Liverpool right-back has dealt over the past couple days, with it yesterday being revealed that he would ditch his surname in favour of going by 'Trent' on the back of his shirt, accompanied by the number 12. Alexander-Arnold has revealed his thinking behind the name change, saying it was purely to avoid confusion rather than a personal rebrand. 'Quite an easy explanation,' he said at his press conference. 'I've always found when I travel to Europe that the whole name situation confuses a lot of people, as there being three names and double-barreled. 'People call me Arnold, people call me Alexander, people call me Alex, people call me Trent, there's a lot that goes on. So I thought let's make it easy, Trent on the back, and be known as Trent. That's my name so I guess that's what people will call me.' Advertisement Alexander-Arnold added that his dilemma over his future was never a question of where to go, admitting he would only ever leave Liverpool for Real Madrid. 'I knew for a long time that I would only leave Liverpool for Real Madrid,' he said. 'No one else. It was never a question of: where do I go? It was always: do I go to Madrid or not? Making that decision wasn't easy.' He also clarified that by saying he had waited a long time to complete a move away from Liverpool, he didn't mean he'd been seeking a new club for 'years'. "To clear that up, by waiting a long time I mean a couple of weeks,' he added. 'Not years. Advertisement "But I am very excited be here. Whether you support the club or not, you have to respect the trophies that the club win. No matter what, that has been always there for me. I have always admired players and clubs that win trophies." The 26-year-old arrives after 20 years at boyhood club Liverpool, joining for a fee of £10m to ensure his participation at the Club World Cup. Trent Alexander-Arnold lifted the Premier League title on his Liverpool sendoff (EPA) The right-back was expected to sign for free at the end of June after opting not to extend his contract at Anfield, an announcement which was made at the beginning of May. Alexander-Arnold was instrumental in Liverpool winning Europe's most prestigious trophy that year, and later added two Premier League titles, two Carabao Cups, an FA Cup and a Club World Cup to his accolade collection across 354 appearances. Advertisement The Liverpudlian left his home side on imperfect terms, with his first appearance after announcing his departure seeing him booed by the Anfield faithful. However, as he collected his Premier League winners medal on the final day of the season, a teary-eyed Alexander-Arnold was met with cheers in what was heart-warming send-off. Watch every Fifa Club World Cup game free on DAZN. Sign up here now.

Trent Alexander-Arnold speaks Spanish as he describes ‘dream' Real Madrid move
Trent Alexander-Arnold speaks Spanish as he describes ‘dream' Real Madrid move

Yahoo

time4 hours ago

  • Yahoo

Trent Alexander-Arnold speaks Spanish as he describes ‘dream' Real Madrid move

Trent Alexander-Arnold said joining Real Madrid was a 'dream come true' as he delivered his opening address to club dignitaries and invited guests in Spanish. The 26-year-old England international, who has signed a six-year deal after his contract with Liverpool expired, was watched by his family as he spoke confidently at his official presentation ahead of a press conference. Advertisement His choice to speak in the language of his new club and not English surprised many but showed the preparation which had gone into this move, something for which he was criticised by sections of the Liverpool fanbase after leaving the club on a free transfer. 'This doesn't happen every day, it's a dream come true and I'm very happy and proud to be here,' he said after his 20-year association with Liverpool officially came to an end. 'I want to show Real Madrid fans how I play; I'm going to give my all for the team and Real Madrid fans. 'I want to show those fans how I play, I want to win many titles and I want to be a winner here and enjoy playing alongside the many great players.' Advertisement Alexander-Arnold, wearing a black suit and tie, sat next to girlfriend Estelle Behnke as a video montage was played of his best moments in a Liverpool shirt, inevitably featuring his two assists in the 4-0 Champions League semi-final comeback against Real's arch-rivals Barcelona. His mum Dianne, sat alongside his dad Michael and brothers Tyler – his agent – and Marcell – could be seen wiping away tears as the video concluded. Real president Florentino Perez described Alexander-Arnold as: 'A player who has won everything, one of the best defenders and full-backs in world football. 'One on the greatest players worldwide is joining this club and hopefully we can write a new page in the history books.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store